Lynparza

In what could be the final approval for the year, the FDA OK'ed a label expansion Monday for Lynparza, which is being co-developed by Merck & Co., Inc. (NYSE: MRK) and AstraZeneca plc (NYSE: AZN). Lynparza's Fourth Approval Merck and AstraZeneca said the FDA has approved Lynparza...

Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc (NASDAQ: CLVS) and TESARO Inc (NASDAQ: TSRO) ahead of the Lynparza label decision. AstraZeneca plc (ADR) (NYSE: AZN)'s Lynparza is a poly polymerase, or PARP, inhibitor indicated for use as a monotherapy in patients...

TESARO Inc (NASDAQ: TSRO) announced the FDA approval of Zejula (niraparib) in recurrent ovarian cancer maintenance with a broad label. The approval came in three months ahead of schedule and the launch is expected in late April, Baird’s Michael E. Ulz said in a report. While reiterating a...

Shares of TESARO Inc (NASDAQ: TSRO) fell more than 10 percent Tuesday after AstraZeneca plc (ADR) (NYSE: AZN) presented better trial results for its ovarian cancer drug. In a related development, shares of Clovis Oncology Inc (NASDAQ: CLVS) gained more than 10 percent to set a new 52-week high of $...

Following AstraZeneca plc (ADR) (NYSE: AZN)’s strong start to 2017, including a positive data report for breast cancer treatment Lynparza, investors await a barrage of news highlighting significant findings and potential approvals for various portfolio components. Updates on immuno-oncology...

The incidence of ovarian cancer is supposed to be sporadic, with just about 3 percent of cancers among women said to originate from the ovaries. However, it is considered more lethal than any other cancer of female reproductive system. Clovis' Slice Of Luck So when the FDA granted accelerated...

AstraZeneca plc (ADR) (NYSE: AZN) announced that Lynparza, which has already received approval for ovarian cancer, failed to meet the overall survival endpoint in gastric cancer in the PII GOLD trials. Sachin Jain of Bank of America Merrill Lynch maintains a Buy rating on the company, with a price...